How were the Sjögren’s Syndrome Foundation (SSF) guidelines formulated for the treatment of inflammatory musculoskeletal pain in Sjögren syndrome?

Updated: Mar 05, 2021
  • Author: Sriya K Ranatunga, MD, MPH; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

The SFF guidelines advise that physicians consider the individual patient’s circumstances when weighing risks and benefits of each therapy. Insufficient evidence exists on the effectiveness of disease-modifying antirheumatic drugs (DMARDs) in the treatment of inflammatory musculoskeletal pain in primary Sjögren syndrome, so recommendations were formulated on the basis of expert opinion as guided by the consensus group process.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!